経口プロプラノロールの休息,運動,運動後の左心室機能に対する効果は,正常な被験者および冠動脈疾患の患者における正常な被験者および冠動脈疾患の患者における左心室機能に対する効果
Circulation
|March 1, 1981
まとめ
プロプラノロルは静止状態の心臓機能に影響を与えなかったが,健康な個体では運動能力を低下させた. 冠動脈疾患の患者では,運動が誘発されたイシュケミアのときのみ機能を改善し,病気の心臓筋の感度が増加することを示唆しました.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
背景:
- ベータアドレナージックブロックは,心血管疾患の管理の礎石です.
- プロプラノロルが心室の機能に与える影響を理解することは,患者のケアを最適化するために不可欠です.
研究 の 目的:
- 口服プロプラノロールの休息,運動,および運動後の心室機能に対する効果を評価する.
- 健康なボランティアと冠動脈疾患の患者の両方でこれらの効果を評価するために.
主な方法:
- マルチゲート均衡心臓血液プールイメージング (MUG-CEPI) を利用しました.
- 静止状態,運動中,運動後の心房機能の評価.
- 中間および最大ベータ阻害を達成するために,プロプラノロルのさまざまな用量を投与した.
主要な成果:
- プロプラノロルは,正常な被験者や冠動脈疾患患者の基礎左心房機能に効果を示さなかった.
- 運動中の正常な被験者において,用量依存の負のイノトロプ効果が観察されました.
- 運動による性不全の冠動脈疾患患者の場合,プロプラノロールは心室のパフォーマンスを改善しました.
- 正常な運動反応を有する冠動脈疾患の患者では,有意な効果は観察されなかった.
結論:
- 発血性心筋梗塞は,β阻害効果に対する感受性の高まりを示しています.
- 冠動脈疾患における運動室機能に対するプロプラノロルの影響は,不全性機能の存在に左右される.
- 効果は,心室前負荷と後負荷の変化とは無関係でした.
関連する概念動画
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:29Pathophysiology of Cardiac Performance
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...